Generic filters
Filter by content type
Taxonomy terms

ANGN – Angion Biomedica Corp


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 4.75

Low: 1.5

High: 8

Total Analysts: 3

Company Profile

Angion Biomedica Corp. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. The Company’s products include ANG-3070, ROCK2 Inhibitor, CYP11B2 Inhibitor and ANG-3777. ANG-3070 is a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung. The Company provides ANG-3070 for Fibrotic Diseases; ANG-3070 for Renal Fibrosis; ANG-3070 for Pulmonary Fibrosis. ROCK2 Inhibitor program targeted towards the treatment of fibrotic diseases. CYP11B2 Inhibitor program targeted towards diseases related to aldosterone synthase dysregulation. ANG-3777 is designed to mimic the biological activity of HGF and to treat acute organ injuries, such as delayed graft function.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan